In order for us to best serve you and provide you with the best information, can you please tell us if you currently have health insurance? In patients ≥65 years of age (all randomized population; capecitabine 188 patients, 5-FU/LV 208 patients) treated for Dukes' C colon cancer after resection of the primary tumor, the hazard ratios for disease-free survival and overall survival for XELODA compared to 5-FU/LV were 1.01 (95% C.I. In patients with moderate renal impairment (baseline creatinine clearance = 30 to 50 mL/min), a dose reduction to 75% of the XELODA starting dose when used as monotherapy or in combination with docetaxel (from 1250 mg/mCreatinine clearance for females = 0.85 × male valuePhysicians should exercise caution in monitoring the effects of XELODA in the elderly. The most frequently reported laboratory abnormalities (per-patient incidence ≥40%) were increased ALT (75%), lymphocytopenia (73%), leukopenia (73%), hypokalemia (68%), thrombocytopenia (57%), hypoalbuminemia (55%), neutropenia (50%), low hematocrit (50%), hypocalcemia (48%), hypophosphatemia (45%) and hyponatremia (45%).Physicians should pay particular attention to monitoring the adverse effects of XELODA in the elderly Exercise caution when patients with mild to moderate hepatic dysfunction due to liver metastases are treated with XELODA. Medical management of overdose should include customary supportive medical interventions aimed at correcting the presenting clinical manifestations. Following grade 3 hand-and-foot syndrome, subsequent doses of XELODA should be decreased In 875 patients with either metastatic breast or colorectal cancer who received at least one dose of XELODA 1250 mg/mIn the 596 patients treated with XELODA as first-line therapy for metastatic colorectal cancer, the incidence of grade 3 or 4 hyperbilirubinemia was similar to the overall clinical trial safety database of XELODA monotherapy.
Altogether, in both trials, 603 patients were randomized to treatment with XELODA at a dose of 1250 mg/mIn both trials, overall survival, time to progression and response rate (complete plus partial responses) were assessed. It was demonstrated that the percent of the survival effect of 5-FU/LV maintained was at least 61% for Study 2 and 10% for Study 1. 6.Hassan Y, Awaisu A, Aziz NA, Ismail O. eMedTV serves only as an informational resource. Taking Xeloda at the same time as phenytoin can lead to phenytoin toxicity.
See full prescribing information for XELODA®. Oral administration of capecitabine to pregnant monkeys during the period of organogenesis at a dose of 90 mg/kg/day, caused fetal lethality. Your healthcare provider should closely monitor the level of phenytoin in your blood and adjust your phenytoin dosage as necessary.Taking capecitabine with warfarin can increase your risk of bleeding.
In order to assure that XELODA has a clinically meaningful survival effect, statistical analyses were performed to determine the percent of the survival effect of 5-FU/LV that was retained by XELODA. In general, these medications should not be taken together.Capecitabine can increase the level of phenytoin in your blood, increasing the risk of phenytoin side effects.
XELODA was administered at a dose of 1255 mg/mAntitumor responses for patients with disease resistant to both paclitaxel and an anthracycline are shown in For the subgroup of 43 patients who were doubly resistant, the median time to progression was 102 days and the median survival was 255 days. Are special precautions needed if I take hydroxycarbamide?Can Keytruda interact with other medications or foods?Antineoplastics are drugs that destroy cancer cells and are primarily used in chemotherapy. Capecitabine metabolites were present in the milk of lactating mice Lactating mice given a single oral dose of capecitabine excreted significant amounts of capecitabine metabolites into the milk.Pregnancy testing is recommended for females of reproductive potential prior to initiating XELODA.XELODA can cause fetal harm when administered to a pregnant woman Based on genetic toxicity findings, advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 3 months following the last dose of XELODA Based on animal studies, XELODA may impair fertility in females and males of reproductive potential The safety and effectiveness of XELODA in pediatric patients have not been established. Insufficient data are available to provide a dosage recommendation.XELODA is supplied as biconvex, oblong film-coated tablets for oral administration.
The peach or light peach film coating contains hydroxypropyl methylcellulose, talc, titanium dioxide, and synthetic yellow and red iron oxides.Enzymes convert capecitabine to 5-fluorouracil (5-FU) The pharmacokinetics of XELODA and its metabolites have been evaluated in about 200 cancer patients over a dosage range of 500 to 3500 mg/mPlasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent.
The median duration of grade 3 to 4 diarrhea was 5 days.
Taking Xeloda at the same time as leucovorin is also extremely dangerous. It is an orally administered systemic prodrug of 5'-deoxy-5-fluorouridine (5'-DFUR) which is converted to 5-fluorouracil.The chemical name for capecitabine is 5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine and has a molecular weight of 359.35.